Contenzioso

03 Jun 15: Sandoz represented by Pavia e Ansaldo obtains nullity of Astrazeneca’s patent for antipsychotic Quetiapine SR QUETIAPINE SR

Sandoz represented by Pavia e Ansaldo obtains nullity of Astrazeneca’s patent for antipsychotic Quetiapine SR QUETIAPINE SR Milan, 3 June 2015 – Pavia e Ansaldo represented Sandoz, the generic pharmaceuticals division of Novartis and one of the global leaders in the field, in the proceedings concerning AstraZeneca’s patent for the sustained release version of quetiapine, a blockbuster antipsychotic medicine whose worldwide market exceeds the value of 1 Billion Euro. The Court of Turin by its decision dated June 1, 2015, declared that the Italian portion of AstraZeneca’s European Patent EP0907364 is null and void. A Panel of Judges, sustaining Sandoz’s legal…